Navigation Links
Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer'
Date:2/7/2008

NEWPORT NEWS, Va., Feb 7 /PRNewswire/ -- Dilon Technologies, makers of a gamma imaging system optimized for early breast cancer detection, has appointed Robert G. Moussa to the position of President and Chief Executive Officer.

Moussa has a long and successful record in the medical device industry having held a number of senior positions at both Sherwood Medical Industries and Mallinckrodt Medical -- a health care corporation he ran as CEO for a number of years. In his four years at Mallinckrodt, Moussa grew revenues from $350 million to $1.2 billion and increased the operating margins from 18 percent to 22 percent. Additionally, he has successfully launched a number of new products in the diagnostic, nuclear medicine and medical device markets.

Dilon "the standard of care"

Regarding Dilon Moussa commented, "Dilon has advanced technology that will make it a major weapon in the battle against cancer. Based upon existing clinical results, it will become the standard of care as an adjunct diagnostic tool in the diagnosis of breast cancer."

4-Point Strategy

Under Moussa's leadership, Dilon will adopt a 4-point strategy to increase market share.
The strategy includes:

1) Expansion of the established installed base in the US through strategic

use of sales and distribution.

2) Initiating a major international expansion strategy. This is based on

Dilon's international potential of being at least as large as that in

the US.

3) Working with the Medical Establishment, expand the capabilities and

indications for the existing BSGI product.

4) Pursue acquisitions of products, technologies and companies that offer

a strategic fit with Dilon.

Moussa added, "I am confident that by adopting and accelerating these measures, we will achieve the objective of making Dilon the standard of care in the diagnostic field."

About Dilon Technologies LLC

Dilon Technologies LLC is bringing innovative new medical products to the market based on research conducted at leading national research laboratories. Dilon's cornerstone product is the Dilon 6800 Gamma Camera -- a high-resolution, anatomic-specific gamma camera, which is now being used to perform Breast-Specific Gamma Imaging (BSGI), a molecular imaging technique that images the metabolic activity of breast lesions through radiotracer uptake. Several leading medical centers around the country are now offering BSGI to their patients, including: Beth Israel Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Alexian Brothers Medical Center, Chicago; Methodist Hospital, Philadelphia; and West Valley Imaging, Las Vegas.

To find out more about BSGI or the Dilon 6800 Gamma Camera please visit http://www.dilon.com


'/>"/>
SOURCE Dilon Technologies LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
4. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
5. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
6. David Mott Appointed Non Executive Director at Shire
7. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
8. John Marshall and Kevin McGuinness Appointed to Ellex Board
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
11. Genelabs Technologies to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):